CXCR4 and neoplasm: Recent in vivo preclinical studies indicated that the combination of small molecule CXCR4 antagonists and anti-PD-1 antibodies significantly enhanced anti-tumor effects compared with single-agent administration in syngeneic murine models of ovarian cancer, colon cancer, and melanoma [150,151].